End Stage Renal Disease clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for

  • Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

    open to eligible people ages 18 years and up

    A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.

    Orange, California and other locations

  • TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done

    Orange, California and other locations

  • Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

    Sorry, accepting new patients by invitation only

    This study will evaluate the long term safety and efficacy of AT-1501 (tegoprubart) compared with tacrolimus in patients undergoing kidney transplantation.

    Orange, California and other locations

Our lead scientists for End Stage Renal Disease research studies include .

Last updated: